Overview

H2 Haplotype and CYP3As Polymorphisms and the Antiplatelet Response to Clopidogrel

Status:
Completed
Trial end date:
2006-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to assess whether interpatient variability in the platelet response to clopidogrel is partly due to polymorphisms of the hepatic cytochrome P450 (CYP450)3A and of the clopidogrel-P2Y12 receptor genes.
Phase:
Phase 4
Details
Lead Sponsor:
Hopital du Sacre-Coeur de Montreal
Treatments:
Clopidogrel
Ticlopidine